{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:20:10Z","timestamp":1785882010481,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s12328-020-01296-0","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T15:07:54Z","timestamp":1606230474000},"page":"684-689","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Successful response of primary sclerosing cholangitis and associated ulcerative colitis to oral vancomycin may depend on brand and personalized dose: report in an adolescent"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8309-6914","authenticated-orcid":false,"given":"Cynthia W.","family":"Buness","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5807-7866","authenticated-orcid":false,"given":"Kevin M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8553-7744","authenticated-orcid":false,"given":"Ahmad Hassan","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4507-2476","authenticated-orcid":false,"given":"Leina","family":"Alrabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1046-5621","authenticated-orcid":false,"given":"Keith D.","family":"Lindor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7767-1537","authenticated-orcid":false,"given":"Tamir","family":"Miloh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth L.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,24]]},"reference":[{"key":"1296_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/ajg.2015.112","volume":"110","author":"KD Lindor","year":"2015","unstructured":"Lindor KD, Kowdley KV, Harrison ME, et al. ACG clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol. 2015;110:646\u201359 (quiz 660).","journal-title":"Am J Gastroenterol"},{"key":"1296_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.cgh.2008.10.019","volume":"7","author":"T Miloh","year":"2009","unstructured":"Miloh T, Arnon R, Shneider B, et al. A retrospective single-center review of primary sclerosing cholangitis in children. Clin Gastroenterol Hepatol. 2009;7:239\u201345.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1296_CR3","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1053\/jhep.2003.50289","volume":"38","author":"AE Feldstein","year":"2003","unstructured":"Feldstein AE, Perrault J, El-Youssif M, et al. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology. 2003;38:210\u20137.","journal-title":"Hepatology"},{"key":"1296_CR4","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3390\/cells9030736","volume":"9","author":"L Maroni","year":"2020","unstructured":"Maroni L, Ninfole E, Pinto C, et al. Gut\u2013liver axis and inflammasome activation in cholangiocyte pathophysiology. Cells. 2020;9:736. https:\/\/doi.org\/10.3390\/cells9030736.","journal-title":"Cells"},{"key":"1296_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4254\/wjh.v11.i1.19","volume":"11","author":"TJ Laborda","year":"2019","unstructured":"Laborda TJ, Jensen MK, Kavan M, et al. Treatment of primary sclerosing cholangitis in children. World J Hepatol. 2019;11:19\u201336.","journal-title":"World J Hepatol"},{"key":"1296_CR6","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","volume":"129","author":"R Olsson","year":"2005","unstructured":"Olsson R, Boberg KM, de Muckadell OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology. 2005;129:1464\u201372.","journal-title":"Gastroenterology"},{"key":"1296_CR7","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/hep.23082","volume":"50","author":"KD Lindor","year":"2009","unstructured":"Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50:808\u201314.","journal-title":"Hepatology"},{"key":"1296_CR8","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3109\/00365521.2014.913189","volume":"49","author":"JH Tabibian","year":"2014","unstructured":"Tabibian JH, O\u2019Hara SP, Lindor KD. Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies. Scand J Gastroenterol. 2014;49:901\u20138.","journal-title":"Scand J Gastroenterol"},{"key":"1296_CR9","doi-asserted-by":"publisher","first-page":"814","DOI":"10.14309\/ajg.0000000000000604","volume":"115","author":"A Shah","year":"2020","unstructured":"Shah A, Macdonald GA, Morrison M, et al. Targeting the gut microbiome as a treatment for primary sclerosing cholangitis: a conceptional framework. Am J Gastroenterol. 2020;115:814\u201322.","journal-title":"Am J Gastroenterol"},{"key":"1296_CR10","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/apt.14540","volume":"47","author":"JL Damman","year":"2018","unstructured":"Damman JL, Rodriguez EA, Ali AH, et al. Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis. Aliment Pharmacol Ther. 2018;47:886\u201395.","journal-title":"Aliment Pharmacol Ther"},{"key":"1296_CR11","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1080\/00365521.2020.1787501","volume":"55","author":"AH Ali","year":"2020","unstructured":"Ali AH, Damman J, Shah SB, et al. Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis. Scand J Gastroenterol. 2020;55:941\u201350.","journal-title":"Scand J Gastroenterol"},{"key":"1296_CR12","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.biotechadv.2018.02.009","volume":"36","author":"GL Marcone","year":"2018","unstructured":"Marcone GL, Binda E, Berini F, et al. Old and new glycopeptide antibiotics: from product to gene and back in the post-genomic era. Biotechnol Adv. 2018;36:534\u201354.","journal-title":"Biotechnol Adv"},{"key":"1296_CR13","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1128\/AAC.01044-09","volume":"54","author":"O Vesga","year":"2010","unstructured":"Vesga O, Agudelo M, Salazar BE, et al. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob Agents Chemother. 2010;54:3271\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"1296_CR14","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1128\/AAC.03710-14","volume":"59","author":"A Louie","year":"2015","unstructured":"Louie A, Boyne MT, Patel V, et al. Pharmacodynamic evaluation of the activities of six parenteral vancomycin products available in the United States. Antimicrob Agents Chemother. 2015;59:622\u201332.","journal-title":"Antimicrob Agents Chemother"},{"key":"1296_CR15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.5223\/pghn.2016.19.3.210","volume":"19","author":"C Buness","year":"2016","unstructured":"Buness C, Lindor KD, Miloh T. Oral vancomycin therapy in a child with primary sclerosing cholangitis and severe ulcerative colitis. Pediatr Gastroenterol Hepatol Nutr. 2016;19:210\u20133.","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"key":"1296_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000001065","author":"JG Buness","year":"2019","unstructured":"Buness JG, Ali AH, Tabibian JH, et al. Potential association of doxycycline with the onset of primary sclerosing cholangitis: a case series. Am J Ther. 2019. https:\/\/doi.org\/10.1097\/MJT.0000000000001065 ((published ahead of print)).","journal-title":"Am J Ther"},{"key":"1296_CR17","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1053\/j.gastro.2008.01.042","volume":"134","author":"E Bjornsson","year":"2008","unstructured":"Bjornsson E, Olsson R, Bergquist A, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology. 2008;134:975\u201380.","journal-title":"Gastroenterology"},{"key":"1296_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/MPG.0b013e31816fee95","volume":"47","author":"YK Davies","year":"2008","unstructured":"Davies YK, Cox KM, Abdullah BA, et al. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr. 2008;47:61\u20137.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1296_CR19","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/hep.31311","volume":"72","author":"G Dean","year":"2020","unstructured":"Dean G, Hanauer S, Levitsky J. The role of the intestine in the pathogenesis of primary sclerosing cholangitis: evidence and therapeutic implications. Hepatology. 2020;72:1127\u201338.","journal-title":"Hepatology"},{"key":"1296_CR20","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/apt.12232","volume":"37","author":"JH Tabibian","year":"2013","unstructured":"Tabibian JH, Weeding E, Jorgensen RA, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis\u2014a pilot study. Aliment Pharmacol Ther. 2013;37:604\u201312.","journal-title":"Aliment Pharmacol Ther"},{"key":"1296_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/314292","author":"YK Davies","year":"2013","unstructured":"Davies YK, Tsay CJ, Caccamo DV, et al. Successful treatment of recurrent primary sclerosing cholangitis after orthotopic liver transplantation with oral vancomycin. Case Rep Transplant. 2013. https:\/\/doi.org\/10.1155\/2013\/314292 ((publication ahead of print)).","journal-title":"Case Rep Transplant"},{"key":"1296_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31560","author":"MR Deneau","year":"2020","unstructured":"Deneau MR. Oral vancomycin, ursodeoxycholic acid or no therapy for pediatric primary sclerosing cholangitis: a matched analysis. Hepatology. 2020. https:\/\/doi.org\/10.1002\/hep.31560 ((publication ahead of print)).","journal-title":"Hepatology"},{"key":"1296_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0162-3109(96)00156-7","volume":"35","author":"M Siedlar","year":"1997","unstructured":"Siedlar M, Szczepanik A, Wi\u0229ckiewicz J, et al. Vancomycin down-regulates lipopolysaccharide-induced tumour necrosis factor alpha (TNF\u03b1) production and TNFa-mRNA accumulation in human blood monocytes. Immunopharmacology. 1997;35:265\u201371.","journal-title":"Immunopharmacology"},{"key":"1296_CR24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10875-012-9801-1","volume":"33","author":"DN Abarbanel","year":"2013","unstructured":"Abarbanel DN, Seki SM, Davies Y, et al. Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis. J Clin Immunol. 2013;33:397\u2013406.","journal-title":"J Clin Immunol"},{"key":"1296_CR25","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41564-018-0333-1","volume":"4","author":"N Nakamoto","year":"2019","unstructured":"Nakamoto N, Sasaki N, Aoki R, et al. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol. 2019;4:492\u2013503.","journal-title":"Nat Microbiol"},{"key":"1296_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/CEG.S186097","volume":"12","author":"BP Vaughn","year":"2019","unstructured":"Vaughn BP, Kaiser T, Staley C, et al. A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis. Clin Exp Gastroenterol. 2019;12:9\u201319.","journal-title":"Clin Exp Gastroenterol"},{"key":"1296_CR27","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3349\/ymj.2020.61.4.301","volume":"61","author":"HK Kim","year":"2020","unstructured":"Kim HK, Choi SM, Kang G, et al. Comparison of in vivo pharmacokinetics and pharmacodynamics of vancomycin products available in Korea. Yonsei Med J. 2020;61:301\u20139.","journal-title":"Yonsei Med J"},{"key":"1296_CR28","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1016\/j.xphs.2020.03.012","volume":"109","author":"M Sauter","year":"2020","unstructured":"Sauter M, Uhl P, Meid AD, et al. New insights into the pharmacokinetics of vancomycin after oral and intravenous administration: an investigation in beagle dogs. J Pharm Sci. 2020;109:2090\u20134.","journal-title":"J Pharm Sci"},{"key":"1296_CR29","unstructured":"FDA Advisory Committee meeting and ViroPharma letter, 2009. https:\/\/www.wayback.archive-it.org\/7993\/20170405230228. https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmacology\/UCM175010.pdf . Accessed 12 Sept 2020."},{"key":"1296_CR30","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1148\/radiol.2017161398","volume":"217","author":"SD Serai","year":"2017","unstructured":"Serai SD, Obuchowski NA, Venkatesh SK, et al. Repeatability of MR elastography of liver: a meta-analysis. Radiology. 2017;217:92\u2013100.","journal-title":"Radiology"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-020-01296-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12328-020-01296-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-020-01296-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T20:40:03Z","timestamp":1617309603000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12328-020-01296-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,24]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1296"],"URL":"https:\/\/doi.org\/10.1007\/s12328-020-01296-0","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,24]]},"assertion":[{"value":"6 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Cynthia W. Buness, Kevin M. Johnson, Ahmad Hassan Ali, Leina Alrabadi, Keith D. Lindor, Tamir Miloh, and Kenneth L. Cox, M.D. all declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights"}},{"value":"Informed consent was obtained from the patient for being included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}